Clinical Research Directory
Browse clinical research sites, groups, and studies.
FDG PET/CT in Breast Cancer Bone Mets
Sponsor: University of Pennsylvania
Summary
This study will evaluate baseline uptake on a FDG PET/CT scan in patients with breast cancer that has spread to the bones. A repeat FDG PET/CT scan will be done 4 weeks after the start of new breast cancer hormone treatment and again at 12 weeks after treatment start. The baseline uptake and change in uptake after the repeat scans will be compared to clinical long term outcomes such as time to progression and overall survival. In addition the uptake will be compared to the incidence of skeletal related events that are common occurrences in patients with cancer that has spread to the bones.
Official title: 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) for the Evaluation of Response to Therapy in Bone-dominant Metastatic Breast Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
75
Start Date
2013-09
Completion Date
2026-07-31
Last Updated
2025-09-02
Healthy Volunteers
No
Interventions
FDG PET/CT scan
\[18F\] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
Locations (1)
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, United States